Guy Jérusalem
Impact in
- Cancer Research top 0.5%
- Breast Cancer Treatment Studies
- Oncology top 0.5%
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
Papers in
- Oncology 102
- HER2/EGFR in Cancer Research 26
- Cancer survivorship and care 23
- Cancer Immunotherapy and Biomarkers 17
-
- Advanced Breast Cancer Therapies 65
- Co-authors
- Georges Fillet (23 shared papers)Yves P. Beguin (18 shared papers)Marie‐France Fassotte (13 shared papers)Fadi Najjar (7 shared papers)P. Rigo (7 shared papers)Joëlle Collignon (17 shared papers)Roland Hustinx (19 shared papers)Laurence Lousberg (3 shared papers)
- Journals
- Annals of Oncology (44 papers)Journal of Geriatric Oncology (10 papers)Breast Cancer Research and Treatment (9 papers)European Journal of Cancer (9 papers)The Lancet Oncology (7 papers)
- Partner nations
- BelgiumUnited StatesItaly
In The Last Decade
Guy Jérusalem
295 papers receiving 16.7k citations
Guy Jérusalem's Hit Papers
Peers
Comparison fields: 5 of 147
- Cancer Research 2.8k
- Oncology 4.1k
- Pulmonary and Respiratory Medicine 3.7k
- Cardiology and Cardiovascular Medicine 2.6k
- Pathology and Forensic Medicine 1.4k
Countries citing papers authored by Guy Jérusalem
This map shows the geographic impact of Guy Jérusalem's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guy Jérusalem with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guy Jérusalem more than expected).
Fields of papers citing papers by Guy Jérusalem
This network shows the impact of papers produced by Guy Jérusalem. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guy Jérusalem. The network helps show where Guy Jérusalem may publish in the future.
Co-authors
The 25 scholars most cited alongside Guy Jérusalem, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 302 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging Hit paper breakdown → | 2014 | 1425 |
| 2 | Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3 Hit paper breakdown → | 2018 | 872 |
| 3 | Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging Hit paper breakdown → | 2014 | 828 |
| 4 | Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study Hit paper breakdown → | 2017 | 645 |
| 5 | Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer Hit paper breakdown → | 2019 | 615 |
| 6 | Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer Hit paper breakdown → | 2010 | 518 |
| 7 | 1999 | 481 | |
| 8 | 2017 | 469 | |
| 9 | 2014 | 416 | |
| 10 | Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial Hit paper breakdown → | 2018 | 404 |
| 11 | 2019 | 393 | |
| 12 | Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy Hit paper breakdown → | 2020 | 377 |
| 13 | Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Hit paper breakdown → | 2022 | 329 |
| 14 | 2016 | 305 | |
| 15 | 2013 | 270 | |
| 16 | Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up Hit paper breakdown → | 2021 | 270 |
| 17 | Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. | 2002 | 259 |
| 18 | 2018 | 229 | |
| 19 | 2001 | 228 | |
| 20 | 2018 | 206 |
About Guy Jérusalem
Guy Jérusalem is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Geriatrics and Gerontology and Radiology, Nuclear Medicine and Imaging, having authored 302 papers that have together received 17.2k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (65 papers), Breast Cancer Treatment Studies (37 papers), HER2/EGFR in Cancer Research (26 papers), Medical Imaging Techniques and Applications (25 papers), Cancer survivorship and care (23 papers), Frailty in Older Adults (21 papers), Lymphoma Diagnosis and Treatment (19 papers) and Cancer Immunotherapy and Biomarkers (17 papers). The work is most often cited by research in Cancer Research (2.8k citations), Oncology (4.1k citations), Pulmonary and Respiratory Medicine (3.7k citations), Cardiology and Cardiovascular Medicine (2.6k citations) and Pathology and Forensic Medicine (1.4k citations). Guy Jérusalem has collaborated with scholars based in Belgium, United States and Italy. Frequent co-authors include Georges Fillet, Yves P. Beguin, Marie‐France Fassotte, Fadi Najjar, P. Rigo, Joëlle Collignon, Roland Hustinx, Laurence Lousberg, Hélène Schroeder and R. Hustinx. Their work appears in journals such as Annals of Oncology, Journal of Geriatric Oncology, Breast Cancer Research and Treatment, European Journal of Cancer and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.